London, United Kingdom

Wen Chean Lim

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations by Wen Chean Lim

Introduction

Wen Chean Lim is a notable inventor based in London, GB. She has made significant contributions to the field of immunotherapy, particularly through her work on chimeric antigen receptors (CARs). With a total of four patents to her name, her innovations are paving the way for advancements in disease treatment.

Latest Patents

Among her latest patents is the invention of a cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors. This invention provides a CAR that binds to a low-density target antigen, which includes a Fab antigen binding domain. The invention also encompasses cells that express such a CAR and their application in treating diseases. Another patent focuses on a similar chimeric antigen receptor, further emphasizing her commitment to developing effective therapeutic solutions.

Career Highlights

Wen Chean Lim is currently associated with Autolus Limited, a company dedicated to advancing cell and gene therapies. Her work at Autolus has been instrumental in pushing the boundaries of what is possible in the realm of cancer treatment and immunotherapy.

Collaborations

She collaborates with talented individuals such as Shaun Cordoba and Simon Thomas, contributing to a dynamic team that is focused on innovative solutions in healthcare.

Conclusion

Wen Chean Lim's contributions to the field of immunotherapy through her patents and work at Autolus Limited highlight her as a leading inventor in the industry. Her innovative approaches are set to make a lasting impact on the treatment of diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…